Published in TB and Outbreaks Week, February 3rd, 2004
Under the terms of the agreement, Aventis Pasteur, the vaccines business of Aventis, receives an exclusive license to research, develop, manufacture, and market cell-based influenza vaccines using Crucell's unique PER.C6 cell line technology. Crucell will receive milestone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.